Pharnext SA
PAR:ALPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Wushang Group Co Ltd
SZSE:000501
|
CN |
|
Kongsberg Gruppen ASA
OTC:KBGGY
|
NO |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (7.3), the stock would be worth €-0 (886% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.9 | €0 |
0%
|
| Industry Average | 7.3 | €-0 |
-886%
|
| Country Average | 7.3 | €-0 |
-879%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Pharnext SA
PAR:ALPHA
|
1.2k EUR | -0.9 | -0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 14.6 | 88 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD | 12.6 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD | 21.3 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 43.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 5.3 |
| Median | 7.3 |
| 70th Percentile | 11.7 |
| Max | 1 862.3 |
Other Multiples
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
